Randomized trial · people

PT-141: desire gains over placebo held across RECONNECT subgroups

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In these trials, bremelanotide's edge over placebo for low desire and related distress was broadly consistent across age, body size and testosterone levels.

Kind
Randomized trial
Studied in
People
Number studied
1202
Published
2022
Journal
J Womens Health (Larchmt)

What they tested

The team tested whether bremelanotide's benefit over placebo for low sexual desire held up across groups split by age, weight, body mass index (BMI) and testosterone level.

How the study was done

A pooled subgroup analysis of two matching randomized, double-blind, placebo-controlled trials in women with hypoactive sexual desire disorder (HSDD, ongoing low sexual desire that causes distress). For 24 weeks, participants injected 1.75 mg bremelanotide or placebo (a dummy shot) under the skin with an autoinjector as needed before sexual activity.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking PT-141? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

Across 1202 patients, bremelanotide led to significant gains in desire and drops in distress about low desire compared with placebo in every age, weight and BMI subgroup and every testosterone quartile, with few exceptions. In women not using hormonal birth control, the rise in desire was significant (p < 0.05). In those using it, the gain was only numerically higher. Distress fell significantly more than with placebo (p < 0.05) whether or not women used hormonal birth control, and gains held with or without low arousal and no matter how long HSDD had lasted.

What it doesn’t show

This splits two trials into smaller subgroups, and a few subgroups, including desire in hormonal birth control users, did not reach a significant result. It covers the 24-week controlled phase, not the longer open-label extension.

The paper

Simon et al. Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide. J Womens Health (Larchmt). 2022.

The compound

More studies on PT-141

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking PT-141? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo